AMIVANTAMAB-VMJW for Lung neoplasm malignant: Side Effects & Safety Data
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
There are 128 adverse event reports in the FDA FAERS database where AMIVANTAMAB-VMJW was used for Lung neoplasm malignant.
Most Reported Side Effects for AMIVANTAMAB-VMJW
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Infusion related reaction | 509 | 25.4% | 17 | 88 |
| Rash | 315 | 15.7% | 9 | 29 |
| Off label use | 130 | 6.5% | 17 | 20 |
| Dyspnoea | 81 | 4.0% | 6 | 14 |
| Paronychia | 78 | 3.9% | 0 | 5 |
| Nausea | 65 | 3.2% | 6 | 9 |
| Oxygen saturation decreased | 55 | 2.7% | 2 | 15 |
| Flushing | 54 | 2.7% | 4 | 4 |
| Death | 53 | 2.6% | 53 | 12 |
| Non-small cell lung cancer | 51 | 2.5% | 21 | 7 |
| Fatigue | 46 | 2.3% | 2 | 8 |
| Product dose omission issue | 45 | 2.2% | 1 | 4 |
| Hypotension | 44 | 2.2% | 4 | 4 |
| Stomatitis | 44 | 2.2% | 0 | 18 |
| Skin toxicity | 42 | 2.1% | 3 | 4 |
Other Indications for AMIVANTAMAB-VMJW
Product used for unknown indication (1,064)
Non-small cell lung cancer (366)
Non-small cell lung cancer metastatic (187)
Egfr gene mutation (89)
Lung adenocarcinoma (67)
Bronchial carcinoma (15)
Non-small cell lung cancer recurrent (12)
Lung cancer metastatic (11)
Metastatic bronchial carcinoma (11)
Lung adenocarcinoma stage iv (8)
Other Drugs Used for Lung neoplasm malignant
ERLOTINIB (9,207)
OSIMERTINIB (4,754)
NIVOLUMAB (4,197)
PEMBROLIZUMAB (3,575)
CARBOPLATIN (3,487)
ALECTINIB (2,932)
PEMETREXED (2,422)
CRIZOTINIB (1,949)
BEVACIZUMAB (1,810)
PACLITAXEL (1,747)